ATE144706T1 - Schizophrenie - Google Patents

Schizophrenie

Info

Publication number
ATE144706T1
ATE144706T1 AT93309286T AT93309286T ATE144706T1 AT E144706 T1 ATE144706 T1 AT E144706T1 AT 93309286 T AT93309286 T AT 93309286T AT 93309286 T AT93309286 T AT 93309286T AT E144706 T1 ATE144706 T1 AT E144706T1
Authority
AT
Austria
Prior art keywords
schizophrenia
efas
treated
combination
cell membrane
Prior art date
Application number
AT93309286T
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE144706T1 publication Critical patent/ATE144706T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT93309286T 1992-11-26 1993-11-22 Schizophrenie ATE144706T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224809A GB9224809D0 (en) 1992-11-26 1992-11-26 Schizophrenia

Publications (1)

Publication Number Publication Date
ATE144706T1 true ATE144706T1 (de) 1996-11-15

Family

ID=10725730

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93309286T ATE144706T1 (de) 1992-11-26 1993-11-22 Schizophrenie

Country Status (19)

Country Link
US (1) US5516800A (de)
EP (2) EP0733360A3 (de)
JP (1) JPH06199663A (de)
CN (1) CN1104494A (de)
AT (1) ATE144706T1 (de)
AU (2) AU666782B2 (de)
CA (1) CA2109777A1 (de)
DE (1) DE69305723T2 (de)
DK (1) DK0599576T3 (de)
ES (1) ES2093935T3 (de)
GB (1) GB9224809D0 (de)
GR (1) GR3021692T3 (de)
HK (1) HK114297A (de)
MY (1) MY109905A (de)
NO (1) NO934266L (de)
NZ (1) NZ250265A (de)
RU (1) RU2123844C1 (de)
SG (1) SG47838A1 (de)
ZA (1) ZA938835B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
ATE264099T1 (de) * 1993-06-09 2004-04-15 Martek Biosciences Corp Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
EP1886679A3 (de) * 1995-06-07 2008-05-28 Martek Biosciences Corporation Verfahren zur Regulierung des Gehalts an mehrfach ungesättigten Fettsäuren in verschiedenen Geweben
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
SK285210B6 (sk) 1996-10-11 2006-09-07 Scarista Limited Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
CA2355341C (en) * 1998-10-15 2009-04-14 Dsm N.V. The use of ara as a supplement for a lactating woman
GB9826899D0 (en) * 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
CA2351469A1 (en) * 1998-12-15 2000-06-22 Susan Marie Kaup Method and composition for the maintenance and restitution of gut integrity
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
AU2002305099A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU2005208832A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1772146A1 (de) * 2005-10-03 2007-04-11 Neuropharma, S.A. Merfach ungesättigte Fettsäuren als BACE-Inhibitoren
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
EP2098229A4 (de) 2006-12-28 2010-03-10 Suntory Holdings Ltd Nervenregenerationsmittel
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2211881A4 (de) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine Zusammensetzungen und verfahren zur prävention und behandlung von krankheiten von säugetieren
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8715914D0 (en) * 1987-07-07 1987-08-12 Efamol Ltd Treatment of cerabral disorders
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia

Also Published As

Publication number Publication date
NO934266D0 (no) 1993-11-25
AU666782B2 (en) 1996-02-22
ES2093935T3 (es) 1997-01-01
AU5232996A (en) 1996-07-18
SG47838A1 (en) 1998-04-17
ZA938835B (en) 1994-08-02
HK114297A (en) 1997-08-29
NZ250265A (en) 1997-06-24
RU2123844C1 (ru) 1998-12-27
NO934266L (no) 1994-05-27
EP0733360A3 (de) 1996-10-02
DE69305723D1 (de) 1996-12-05
EP0733360A2 (de) 1996-09-25
GB9224809D0 (en) 1993-01-13
US5516800A (en) 1996-05-14
GR3021692T3 (en) 1997-02-28
MY109905A (en) 1997-09-30
EP0599576A1 (de) 1994-06-01
EP0599576B1 (de) 1996-10-30
DE69305723T2 (de) 1997-04-03
JPH06199663A (ja) 1994-07-19
CA2109777A1 (en) 1994-05-27
CN1104494A (zh) 1995-07-05
AU5183093A (en) 1994-06-09
DK0599576T3 (da) 1996-11-25

Similar Documents

Publication Publication Date Title
DK0599576T3 (da) Skizofreni
FI901289A0 (fi) Komposition innehaollande d-cykloserin och d-alanin foer foerbaettrande av kognitiva eller psykotiska stoerningar.
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
ES2125358T3 (es) Agentes para la clarificacion del agua con polivinilaminas cuaternizadas.
NO931923D0 (no) Fettsyre-behandling
DE59300135D1 (de) Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone.
FI832592A (fi) Foerfarande foer att utfoera elektromikrobiella reduktioner
NL940019I1 (nl) Remming van het infecterende karakter in vitro en het cytopatische effect van htlv-iii/lav door 2',3'-didesoxycytidine
DE69112192T2 (de) Antiherpes-Castanosperminester.
ATE41940T1 (de) Wasserloesliche copolymerisate und deren verwendung als baustoffhilfsmittel.
ITMI910380A1 (it) Composti steroidei attivi sul sistema cardiovascolare
ATE51520T1 (de) Kosmetikum.
DK435089D0 (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
KR880016581U (ko) 정수 및 살균장치가 장착된 가습기
ES2173158T3 (es) Reduccion del tejido adiposo utilizando colagenasa
UA8391A1 (uk) Джерело живлення
ATE31852T1 (de) Energieversorgung mit gleichstromeingangsquelle und gepulsten stromversorgungsstufen.
DK356689A (da) Optisk forstaerker med nedsat ulinearitet
FI931521A0 (fi) Negativ vridvinkel
SE8500548L (sv) Skyddsrum
KR870007499U (ko) 음방향 피크검출 자동 입력 조절기를 내장한 저전압 증폭기

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee